Clinical improvement in patients with borderline personality disorder after treatment with repetitive transcranial magnetic stimulation: preliminary results

Julian Reyes-López,1 Josefina Ricardo-Garcell, 2 Gabriela Armas-Castañeda, 3 María García-Anaya, 4 Iván Arango-De Montis, 4 Jorge J. González-Olvera, 4 Francisco Pellicer 4

1 Clínica del Sistema Nervioso, Departamento de Investigación Biomédica, Facultad de Medicina, Universidad Autónoma de Querétaro, Querétaro, Mexico. 2 Instituto de Neurobiología, Universidad Nacional Autónoma de México, Juriquilla, Querétaro, Mexico. 3 Departamento de Psiquiatría y Salud Mental, Facultad de Medicina, Universidad Nacional Autónoma de México, Querétaro, Mexico. 4 Instituto Nacional de Psiquiatría Ramón de la Fuente Muníz, Ciudad de México, Mexico.

Objective: Current treatment of borderline personality disorder (BPD) consists of psychotherapy and pharmacological interventions. However, the use of repetitive transcranial magnetic stimulation (rTMS) could be beneficial to improve some BPD symptoms. The objective of this study was to evaluate clinical improvement in patients with BPD after application of rTMS over the right or left dorsolateral prefrontal cortex (DLPFC).

Method: Twenty-nine patients with BPD from the National Institute of Psychiatry, Mexico, were randomized in two groups to receive 15 sessions of rTMS applied over the right (1 Hz, n=15) or left (5 Hz, n=14) DLPFC. Improvement was measured by the Clinical Global Impression Scale for BPD (CGI-BPD), Borderline Evaluation of Severity Over Time (BEST), Beck Depression Inventory (BDI), Hamilton Anxiety Rating Scale (HAM-A), and Barratt Impulsiveness Scale (BIS).

Results: Intragroup comparison showed significant (p < 0.05) reductions in every psychopathologic domain of the CGI-BPD and in the total scores of all scales in both groups.

Conclusions: Both protocols produced global improvement in severity and symptoms of BPD, particularly in impulsiveness, affective instability, and anger. Further studies are warranted to explore the therapeutic effect of rTMS in BPD.

Clinical trial registration: NCT02273674.

Keywords: Borderline personality disorder; neurophysiology; neurosciences; psychosocial factors

Introduction

Borderline personality disorder (BPD) is one of the most common personality disorders in clinical practice. It affects 1% to 5.9% of the general population and accounts for 10% of outpatient psychiatry visits and more than 20% of the psychiatric inpatient population,1,2 generating a huge demand for health services.2 BPD prevalence is similar in both genders,2 although diagnosis is more common in women. The disorder is characterized by persistent patterns of affective instability, problematic relationships, and marked impulsiveness,2 which manifests as self-injurious behavior, substance abuse, suicidality,2,4 and other high-risk behaviors. Comorbidity with disorders such as depression, anxiety, and posttraumatic stress disorder (PTSD) is common.2

Neuroimaging and neuropsychological studies1,2 have shown that the clinical manifestations of BPD are related to changes in the frontolimbic network,2,3 including amygdala hyperactivity and hypofunctionality in prefrontal structures4 such as the orbitofrontal cortex (OFC), the ventromedial prefrontal cortex (VMPFC), and the dorsolateral (DLPFC) cortex.7-9 Particularly, the DLPFC plays a key role in regulating top-down emotional control and impulsiveness.9,10 These findings become relevant when considering that the current lines of treatment are psychotherapy (maintenance treatment) and pharmacological interventions (which are used during exacerbations of symptoms).2

Nevertheless, the use of neuromodulation, such as repetitive transcranial magnetic stimulation (rTMS),11,12 could be beneficial to improve some symptoms of BPD and to normalize the cortical dysfunction associated with these manifestations.13 This technique uses electromagnetic induction14 to stimulate the cerebral cortex focally and noninvasively, with few side effects,15,16 and is relatively pain free. The neuromodulatory action of rTMS involves excitatory and inhibitory neuronal processes and plastic changes.16,17

At present, rTMS has been approved for the treatment of depression in several countries; it is accepted as an evidence-based treatment option by the American
Psychiatric Association (APA), the Canadian Network for Mood and Anxiety Treatments (CANMAT), and the World Federation of Societies of Biological Psychiatry (WFSBP). The most frequent protocols are those using high frequencies (≥ 1 Hz to a maximum of 20 Hz) over the left DLPFC, or low frequencies (≤ 1 Hz) over the right one. Effects have also been demonstrated in psychiatric disorders that share features with BPD, such as impulsivity and anxiety symptoms.

Studies have explored the therapeutic potential of rTMS in BPD using high-frequency protocols (10 Hz) on the right and left DLPFCs, although evidence shows that use of frequencies in the inhibitory (≤ 1 Hz) or 5-Hz ranges can provide clinical benefits with greater tolerability and reduced risk of adverse events. Thus, the aim of this study was to evaluate clinical improvement in patients with BPD after treatment with high-frequency (5 Hz) or low-frequency (1 Hz) rTMS of the left or right DLPFC, respectively.

Material and methods

Participants

Twenty-nine patients with BPD, of both genders (27 women), all right-handed, with an age range of 18-45 years (mean 30.2 years, standard deviation [SD] = 7.6), participated in a randomized clinical trial that was conducted over 12 months. Outpatients from the BPD Clinic of the Ramon de la Fuente Muñiz National Institute of Psychiatry (INPRF) in Mexico City, with a DSM-IV-TR diagnosis of BPD and a score ≥ 8 on the Spanish version of the Borderline Diagnostic Interview Revised (DIB-R) were included.

Subjects with intracranial metallic objects and medical devices contraindicated in transcranial magnetic stimulation (TMS) were excluded, as were subjects with epilepsy, history of seizures, substance dependence, suicidal ideation, psychotic symptoms, bipolar affective disorder, current major depressive episode, and other comorbid psychiatric disorders, except generalized anxiety disorder. To reduce the risk of inducing seizures by rTMS, subjects with epileptiform activity on an electroencephalogram were also excluded. A safety questionnaire was applied in accordance with international guidelines.

All participants received a complete description of the study and provided informed consent. This study was conducted in compliance with the Declaration of Helsinki, was approved by the INPRF Research Ethics Committee, and was registered in the U.S. National Institutes of Health ClinicalTrials.gov platform (www.clinicaltrials.gov) with accession number NCT02273674.

Clinical evaluation of participants

Six clinical tests were administered to assess BPD, anxiety and depressive symptoms, and impulsiveness. To determine the severity of BPD symptoms and their changes over time, the Clinical Global Impression Scale for BPD (CGI-BPD) and the Spanish version of the Borderline Evaluation of Severity Over Time (BEST) were applied. The CGI-BPD is an adaptation of the Clinical Global Impression scale (CGI) that was designed with the objective of evaluating both the severity and the subsequent change in response to an intervention in patients diagnosed with BPD. The CGI consists of 10 Likert-type items scored on a scale of 1 to 7, which evaluate nine psychopathological domains of BPD, and an additional overall score.

CGI-BPD consists of two formats to assess current severity and change over time. The instrument has demonstrated adequate validity, reliability, and sensitivity to change. BEST, in turn, is a self-administered instrument designed to evaluate the severity and change over time of typical thoughts, emotions, and behaviors in BPD. This scale has also demonstrated adequate sensitivity to change, high internal consistency, and discriminant validity.

The Barratt Impulsiveness Scale (BIS) was used to assess impulsiveness. It is self-administered and was validated in Spanish by Oquendo et al. The BIS consists of 30 items grouped into three impulsiveness subscales: cognitive, motor, and unplanned. This test has a high internal consistency.

The presence, severity, and change over time of anxiety and depressive symptoms were evaluated by the Hamilton Anxiety Rating Scale (HAM-A) and a 21-item version of the Beck Depression Inventory (BDI), respectively. Clinimetric tests were applied by an experienced psychiatrist, before and after 15 rTMS sessions, in order to evaluate changes in BPD, anxiety and depressive symptoms, and impulsiveness.

Repetitive transcranial magnetic stimulation procedure

Participants were randomly assigned to receive one of two different rTMS protocols (5 Hz or 1 Hz), which generated two treatment groups. In both protocols, rTMS pulses were administered at an intensity equal to 100% of each patient’s motor threshold using a Dantec MagPro rapid magnetic stimulator and a 50 mm Dantec MC-B70 butterfly (figure-eight) coil with 150° angulation.

The resting motor threshold (RMT) was determined at the start of each session, using the visual inspection method as described by Fitzgerald, in which the abductor pollicis brevis muscle (APBM) motor response is evaluated. Stimulation site was defined as 5 cm above the maximum stimulation point at the APBM region, according to descriptions in previous clinical guidelines for locating the DLPFC.

In the 1 Hz group (n=15, 14 women), rTMS was applied to the right DLPFC (one 15-minute train, 1 pulse per second continuously, for a total of 900 pulses per session). In the 5 Hz group (n=14, 13 women), rTMS was applied to the left DLPFC (30 trains of 10 seconds each, with a 10-second interval between each train, for a total of 1,500 pulses per session). Both rTMS protocols consisted of one daily session from Monday through Friday for 3 weeks (15 sessions total).

Statistical analysis

SPSS version 17 for Windows was used for statistical analysis. Comparison between age groups was performed...
using the nonparametric Mann-Whitney U test, while gender distributions were compared by Fisher’s exact test. To analyze changes in clinimetric test scores, the Mann-Whitney U was used to compare differences between groups, while the Wilcoxon test was used to evaluate the effect of rTMS within each group. Cohen’s d was calculated in Microsoft Excel to analyze the effect size of rTMS on BPD symptoms.

Results

Both treatment groups were relatively homogeneous in terms of age, sex, and baseline symptoms, since there were no statistically significant differences in these variables (Table 1). After application of the rTMS protocols, both groups showed significant reductions in total scores of all instruments (Table 2, Figures 1 and 2).

Borderline personality disorder symptoms and repetitive transcranial magnetic stimulation

The change in the patients’ symptoms, evaluated through the CGI-BPD, was obtained considering the score of each of the first nine BPD psychopathological domains, which assess current severity. The total score was also obtained by adding the scores of each of these nine domains. The Wilcoxon test was used for statistical analysis in both groups, before and after rTMS (Wilcoxon test and Cohen’s d).

Table 1 Statistical analysis of sociodemographic variables (age, sex) and baseline clinical test scores in the two treatment groups

<table>
<thead>
<tr>
<th>Groups</th>
<th>1 Hz (n=15)</th>
<th>5 Hz (n=14)</th>
<th>Statistic</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>29.6±7.8</td>
<td>30.9±7.6</td>
<td>U = 76.5</td>
<td>0.32</td>
</tr>
<tr>
<td>Sex, male/female (% female)</td>
<td>14/13 (93)</td>
<td>13/13 (92)</td>
<td>Fisher’s exact test</td>
<td>0.9</td>
</tr>
<tr>
<td>BDI</td>
<td>30.9±15.6</td>
<td>31.9±14.6</td>
<td>U = 97.5</td>
<td>0.982</td>
</tr>
<tr>
<td>HAM-A</td>
<td>20.2±6.8</td>
<td>15.5±6.4</td>
<td>U = 33</td>
<td>0.120</td>
</tr>
<tr>
<td>CGI-BPD</td>
<td>41.1±4.7</td>
<td>40.2±6.0</td>
<td>U = 91.0</td>
<td>0.747</td>
</tr>
<tr>
<td>BEST</td>
<td>41.0±14.5</td>
<td>42.8±9.7</td>
<td>U = 65.0</td>
<td>0.510</td>
</tr>
<tr>
<td>Barratt Impulsiveness Scale</td>
<td>70.2±12.0</td>
<td>73.1±14.2</td>
<td>U = 94.0</td>
<td>0.631</td>
</tr>
</tbody>
</table>

Data presented as mean ± standard deviation, unless otherwise specified. BDI = Beck Depression Inventory; BEST = Borderline Evaluation of Severity Over Time; CGI-BPD = Clinical Global Impression Scale for Borderline Personality Disorder; HAM-A = Hamilton Anxiety Rating Scale.

Table 2 Significant differences and effect sizes obtained by comparing values of the nine CGI-BPD domains, in each treatment group, before and after rTMS (Wilcoxon test and Cohen’s d)

<table>
<thead>
<tr>
<th>Domain</th>
<th>1 Hz Pre rTMS</th>
<th>1 Hz Post rTMS</th>
<th>Cohen’s d</th>
<th>5 Hz Pre rTMS</th>
<th>5 Hz Post rTMS</th>
<th>Cohen’s d</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abandonment</td>
<td>4.2±0.8</td>
<td>3.0±1.0</td>
<td>1.37</td>
<td>4.0±0.9</td>
<td>2.9±0.5</td>
<td>1.57</td>
</tr>
<tr>
<td>Unstable relationships</td>
<td>4.2±0.8</td>
<td>3.1±0.8</td>
<td>1.42</td>
<td>4.5±0.7</td>
<td>3.1±0.9</td>
<td>1.8</td>
</tr>
<tr>
<td>Identity</td>
<td>3.7±0.6</td>
<td>3.1±0.9</td>
<td>0.81</td>
<td>3.7±1.0</td>
<td>2.9±1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>Impulsiveness</td>
<td>4.4±0.5</td>
<td>2.6±0.8</td>
<td>2.79</td>
<td>4.0±0.8</td>
<td>2.6±1.1</td>
<td>1.51</td>
</tr>
<tr>
<td>Suicide</td>
<td>3.2±1.3</td>
<td>1.8±0.7</td>
<td>1.39</td>
<td>3.1±0.9</td>
<td>1.9±0.8</td>
<td>1.46</td>
</tr>
<tr>
<td>Affective instability</td>
<td>4.3±0.6</td>
<td>2.9±0.9</td>
<td>2.22</td>
<td>4.4±0.6</td>
<td>2.9±1.0</td>
<td>1.89</td>
</tr>
<tr>
<td>Empty</td>
<td>4.1±1.1</td>
<td>2.9±0.9</td>
<td>1.24</td>
<td>4.2±1.0</td>
<td>3.1±0.9</td>
<td>1.20</td>
</tr>
<tr>
<td>Angry</td>
<td>4.2±0.7</td>
<td>2.6±0.6</td>
<td>2.54</td>
<td>3.9±0.8</td>
<td>2.6±0.8</td>
<td>1.69</td>
</tr>
<tr>
<td>Paranoid ideation</td>
<td>4.4±0.8</td>
<td>3.4±1.1</td>
<td>1.08</td>
<td>4.0±1.4</td>
<td>3.1±1.1</td>
<td>0.74</td>
</tr>
</tbody>
</table>

CGI-BPD = Clinical Global Impression Scale for Borderline Personality Disorder; rTMS = repetitive transcranial magnetic stimulation; SD = standard deviation. *p < 0.005; †p < 0.01; ‡p < 0.05.
differences in BEST total score were found, whether at baseline \((U = 65.0, p > 0.05)\) or after rTMS \((U = 56.0, p > 0.05)\) (Figure 1B).

Regarding individual BEST scale dimensions, significant reductions were observed in both groups for Thoughts and Feelings \((1 \text{ Hz} = 27.1 \pm 8.2 \text{ vs. } 19.9 \pm 8.4, p < 0.05)\).
z = 2.3, p = 0.021, Cohen’s d = 0.90; 5 Hz = 27.2±6.4 vs. 17.0±8.2, z = 2.9, p = 0.003, Cohen’s d = 1.44), representing a percent change of 33.5% for the 1 Hz group and 38.6% for the 5 Hz group, and in Negative Behaviors, with a 17% reduction for the 1 Hz group (9.6±4.4 vs. 7.0±3.5, z = 1.3, p > 0.05, Cohen’s d = 0.68) and a 33.9% reduction for the 5 Hz group (10.9±3.8 vs. 6.5±3.2, z = 2.4, p = 0.014, Cohen’s d = 1.3). In the Positive Behaviors dimension, no significant changes were observed in either 1 Hz group (10.6±3.0 vs. 11.2±2.2, z = -0.8, p = 0.39) or the 5 Hz groups (10.3±2.3 vs. 11.7±1.5, z = 1.4, p = 0.14). There were no significant between-group differences in individual BEST dimension scores at baseline or after rTMS (Figure 2A).

Impulsiveness

Comparison of baseline and post-treatment BIS scores showed significant reductions in total scores in the 1 Hz group (70.2±12.0 vs. 57.3±14.8, z = 3.2, p = 0.001, Cohen’s d = 0.99) and the 5 Hz group (73.1±14 vs. 63.3±12.1, z = 2.3, p = 0.017, Cohen’s d = 0.78), with change percentages of 18.96% and 11.83% respectively. No between-groups differences in impulsiveness scores were observed at baseline (U = 94.0, p > 0.05) or after magnetic stimulation sessions (U = 87.0, p > 0.05) (Figure 1C).

Analysis of changes in BIS dimension scores showed significant reductions for both groups in motor impulsiveness (1 Hz, 24.4±5.0 vs. 16.8±8, z = 2.7 p = 0.007, Cohen’s d = 1.18, 29% change; 5 Hz, 25.5±7.5 vs. 18.9±7.3, z = 2.8 p = 0.004, Cohen’s d = 0.93, 25% change). Additionally, the 1 Hz group showed a significant reduction in cognitive impulsiveness dimension score (20.8±3.7 vs. 18.0±4.6, z = 2.0 p = 0.037, Cohen’s d = 0.69, 13% reduction compared to baseline). There were no significant changes in the Nonplanning impulsiveness dimension. No significant differences were found on between-group comparison (Figure 3).

Anxiety and depressive symptoms

BDI scores reduced significantly from baseline after rTMS in both the 1 Hz group (30.9±15.5 vs. 13±9.1, z = -3.1, p = 0.002, Cohen’s d = 1.46, percent change 49%) and the 5 Hz group (31.9±14.5 vs. 14.2±11.0, z = -3.3, p = 0.001, Cohen’s d = 1.43, percent change 60%). No between-group differences were found at baseline (U = 97.5, p > 0.05) or after rTMS (U = 96.5, p > 0.05) (Figure 1D).

Similarly, HAM-A scores reduced after rTMS treatment in both groups (1 Hz, 20.2±6.8 vs. 8±4.7, z = -2.8, p = 0.005, Cohen’s d = 2.16, percent change 60.3%; 5 Hz, 15.5±6.4 vs. 6.4±3.5, z = -2.9, p = 0.003, Cohen’s d = 1.83, percent change 58.7%). Again, no between-groups differences at baseline (U = 33, p > 0.05) or after rTMS (U = 43, p > 0.05) were found.

Discussion

This is the first study to explore the effect of rTMS, using 5 Hz frequencies on the left DLPFC and 1 Hz on the right DLPFC, on clinical improvement in patients with BPD. Previous studies have demonstrated the effectiveness of these protocols in treating depressive symptoms, besides reducing discomfort and inducing seizure risk.

Although imaging studies and the pathophysiology of BPD suggest dysfunction in the frontolimbic network, including the anterior cingulate cortex (ACC), the orbitofrontal and dorsolateral prefrontal cortex, the hippocampus, and

Figure 3 Changes in Barratt Impulsiveness (BIS) dimensions. Data presented as mean ± standard deviation. * p < 0.005; † p < 0.01; ‡ p < 0.05.
the amygdala, limitations in access due to the design of TMS coils make stimulation of these structures more difficult. For instance, stimulation of the ACC or amygdala requires different coil designs, such as a double-cone angulated coil, Hesed-coil (H-coil), C-core coil, or circular crown-coil. Furthermore, considering the physical discomfort observed during stimulation of other regions (orbitofrontal cortex and frontal pole) using a figure-eight coil, through a pilot study carried out by our research group in healthy volunteers, we decided to use the same anatomical targets reported in previous studies in both BPD and depression.

Unlike in previous reports and treatment guidelines for conditions such as depression, where treatment is suggested to last 2 to 6 weeks of treatment, reports on the application of rTMS in BPD have used only 10-session, 2-week protocols. In this context, we decided to extend the number of sessions by 50% (15 sessions in 3 weeks), within parameters that have been demonstrated to elicit responses in the left and right DLPFC.

It is important to mention that, although it can be considered a soft stimulation parameter, the use of 900 pulses per session is greater than that reported in previous studies for conditions such as depression and PTSD, where a clinical effect has been reported even with protocols administering 120-1,200 pulses per session. Our results showed that both stimulation protocols were effective in reducing BPD symptom severity and several symptoms in particular, such as fear of abandonment, impulsivity, emotional instability, and anger. This may have a positive impact on reduction of self-harm and suicidal behavior, as well as improve family and interpersonal relationships through better social functioning.

After application of an inhibitory frequency (1 Hz) over the right DLPFC, we observed score reductions in every clinimetric scale, particularly in BIS, with a significant decrease in the cognitive impulsiveness subscale. This result is similar to that reported by the Cailhol group, by stimulating the same cortex, but with an excitatory frequency (10 Hz) on the right DLPFC.

Furthermore, using a lower excitatory frequency (5 Hz) on the left DLPFC, we obtained results similar to those reported by Arbabi et al. in a case report, where the same region was stimulated at 10 Hz. In both studies, reductions in depressive affective symptoms and impulsiveness level were observed.

The effect of rTMS is influenced by variables such as frequency and number of pulses. Even if the number of pulses in each rTMS session (1,500) was the same in both protocols; our study was performed in 15 sessions (22,500 total pulses) instead of the 10 sessions (15,000 total pulses) applied in Arbabi’s case, resulting in a larger amount of total pulses. It is reasonable to assume that the significant improvement in every BPD psychopathological domain observed in our results is related to this larger amount of total pulses applied, as Arbabi et al. only found changes in identity, impulsiveness, emotional instability and anger domains.

Evidence supports an association between BPD symptoms (specifically, impulsiveness and affective instability) with a deficit in top-down regulation of emotional processing, due to lower modulation of cortical structures (particularly the DLPFC) over subcortical structures (such as the amygdala). It has also been reported that severity of self-harm in these patients is associated with level of impulsivity, anger, and somatic anxiety. These data are consistent with findings of DLPFC functional disturbances in patients with BPD and microstructural damage to the uncinate fasciculus white matter (WM), the largest WM tract interconnecting the amygdala with prefrontal structures.

Given this background, one could infer that using inhibitory frequencies (< 1 Hz) on frontal structures would have a potentiating effect on BPD symptoms by further reducing DLPFC top-down regulation on the amygdala. However, our results after stimulation of the right DLPFC with 1 Hz suggest otherwise. Although we have no references to explain this effect on BPD symptoms, the use of inhibitory frequencies in other entities (i.e., attention-deficit hyperactivity disorder, Tourette’s syndrome, posttraumatic stress), which share impulse control failure and anxiety symptoms with BPD, suggest that this beneficial effect of rTMS may be attributable to improvement in functional deficits in the frontostriatal circuitry that appear to be associated with impulsivity and affective instability.

Moreover, the effect of excitatory frequencies on the left DLPFC can be interpreted in light of the Valencia Asymmetry Hypothesis, which proposes that emotions associated with anxiety are processed predominantly by the right hemisphere, while the left hemisphere processes emotions related to approach behaviors and positive mood states. Thus, 5 Hz rTMS applied over the left DLPFC could help increase top-down regulation of the amygdala, improving aspects such as impulsivity and affective instability.

Interestingly, both forms of stimulation (1 Hz and 5 Hz) produced global improvement in BPD symptom severity, particularly in impulsiveness, affective instability, and anger. In these sense, the role of laterality and frequency of rTMS have been controversial technical aspects; for example, in previous studies of rTMS in BPD, the authors described improvement of the symptoms with the use of high-frequency protocols, independently of rTMS laterality. Fitzgerald reported absence of a differential effect between right or left rTMS at low frequencies over the DLPFC for depression treatment, while Speer et al. reported that high frequencies (20 Hz) and low frequencies (1 Hz), when applied to the left DLPFC at 110% of RMT, had the same antidepressant effect. Similarly, there are reports of clinical response to right or left rTMS in PTSD.

However, different guidelines recommend the use of protocols with high frequencies over the left DLPFC for treatment of depression and PTSD. Speer et al. 39,40 evaluated the clinical and metabolic effect of protocols with high- and low-frequency rTMS over the left DLPFC through the use of positron emission tomography (PET) to measure changes in absolute regional cerebral blood flow. They reported that only high frequencies (20 Hz) were associated with increased global blood flow in the left prefrontal cortex, left cingulate gyrus, and left amygdala, as well as bilateral insula, basal ganglia, uncus.
hippocampus, parahippocampus, thalamus, and cerebelum; with low frequencies (1 Hz), the authors found decreases in blood flow in the right prefrontal cortex, left medial temporal cortex, left basal ganglia, and left amygdala. In a second study, the same authors showed that improvement with the use of high-frequency rTMS (20 Hz) was associated with hyperperfusion on baseline PET. In this sense, these papers showed differential effects of high vs. low frequencies in metabolic response to rTMS over the left DLPFC, although clinical response was reported with both protocols of rTMS.

Among the limitations of this preliminary report, we must consider that the sample size was small, there was no sham group, and we did not use neurophysiology or neuroimaging techniques which might have revealed anatomical and functional changes associated with the clinical benefits of our rTMS protocols. Despite published studies on BPD and rTMS, we did not consider inclusion of a sham group essential, because ours is an exploratory study about the potential therapeutic effect of rTMS in the treatment of BPD. A report by Cailhol et al. reported comparative results between five patients who received active treatment with rTMS and five sham subjects, and although they did not find significant differences between the two groups in clinical scales, cognitive improvement was reported in the active group. Therefore, differences in active vs. sham treatment have not been demonstrated yet. It is essential that future studies include sham groups, as partial responses to sham treatment have been found in other conditions, such as depression.

Despite the limitations mentioned above, our results support the use of rTMS as a supplemental treatment for BPD. Considering that BPD is the most common personality disorder in clinical practice, further studies are warranted to explore the potential therapeutic effect of rTMS in this condition.

Acknowledgements
The authors wish to thank the National Council of Science and Technology (CONACyT), Mexico, for granting a doctoral scholarship (CVU/Scholar: 228471/210582).

The authors are grateful to the Ramon de la Fuente Muñiz National Institute of Psychiatry, to Erik Daniel Morelos, and to all participants included in the study for their support. We also thank Hector García Castro for his support in the English translation of the article.

Disclosure
The authors report no conflicts of interest.

References